MARKET WIRE NEWS

Cannara Announces Graduation to the Toronto Stock Exchange

MWN-AI** Summary

Cannara Biotech Inc., a vertically integrated cannabis producer based in Québec, has announced its graduation from the TSX Venture Exchange (TSXV) to the Toronto Stock Exchange (TSX). This uplisting marks a significant milestone for the company, enhancing its market visibility and liquidity, and providing broader access to institutional investors. Cannara operates two large facilities covering over 1.6 million square feet, with the capacity to produce 100,000 kg of premium-grade cannabis annually, leveraging Québec's energy cost advantages.

Zohar Krivorot, the company’s Founder and CEO, expressed pride in this transition, highlighting its importance in Cannara’s growth strategy and commitment to long-term shareholder value. Trading on the TSX will commence on March 2, 2026, under the ticker symbol "LOVE," with shares being delisted from the TSXV simultaneously. To commemorate this achievement, Cannara will participate in the market opening at the TSX on March 17, 2026.

Additionally, Cannara announced that TD Cowen has initiated coverage on the company, providing research insights available on their platform. However, the opinions expressed by TD Cowen do not necessarily reflect Cannara's views nor indicate company endorsement.

The announcement emphasizes Cannara's strategic positioning within Canada’s competitive cannabis market, focusing on producing high-quality products at affordable prices. The company aims to build on its current momentum to capitalize on growth opportunities while also cautioning stakeholders regarding the inherent risks and uncertainties associated with forward-looking statements. Overall, Cannara's uplisting to the TSX reflects its progress as a public entity, setting the stage for future developments in the evolving cannabis industry.

MWN-AI** Analysis

Cannara Biotech Inc.'s recent graduation to the Toronto Stock Exchange (TSX) marks a pivotal moment in the company’s evolution and reflects a solid growth trajectory within the cannabis sector. This uplift not only enhances Cannara's visibility but also broadens its access to institutional investors, which can substantially escalate the trading volume and liquidity of its shares post-transition from the TSX Venture Exchange (TSXV).

Investors should consider this uplisting as a signal of Cannara's commitment to long-term shareholder value. The company's expansive facilities in Québec, combined with its affordable pricing strategy, positions it well to capitalize on the growing demand for premium cannabis products. With the capability to produce 100,000 kg of cannabis annually and the advantage of low electricity costs, Cannara is well-equipped to meet market needs effectively.

Moreover, the initiation of coverage by TD Cowen indicates burgeoning interest and potential validation from analysts, which may foster additional confidence among investors. However, while this momentum appears promising, investors should note the inherent risks that can impact future performance, as highlighted in Cannara's cautionary statements. Market volatility and regulatory hurdles in the cannabis industry remain significant concerns that could affect the company's ability to deliver expected results.

Current and prospective investors should monitor the stock carefully around its trading debut on March 2, 2026. Participation in this uplisting could present a unique opportunity to invest in a company poised for growth in a rapidly evolving market. Nevertheless, thorough research and an understanding of market dynamics will be crucial in navigating potential risks associated with the cannabis sector. Always consider diversifying your investments to mitigate exposure as the market continues to develop.

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.

Source: GlobeNewswire

MONTREAL, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities based in Québec spanning over 1,600,000 sq. ft., is pleased to announce that it has received final approval to graduate (the "Uplisting") from the TSX Venture Exchange to the Toronto Stock Exchange (the "TSX").

"Graduating to the TSX represents a significant milestone in Cannara's evolution as a public company," said Zohar Krivorot, Founder and CEO of Cannara. "This achievement enhances our market visibility and liquidity while broadening our accessibility to institutional investors. It reflects the progress we have made as an organization and our commitment to building long-term shareholder value as we continue executing on our growth strategy."

In connection with the Uplisting, the Company's common shares will commence trading on the TSX at the opening of the market on March 2, 2026, under the trading symbol "LOVE". Concurrently, the Company's common shares will be delisted from the TSXV effective March 2, 2026. To celebrate this milestone, Cannara will have the honour of opening the market at the TSX on March 17, 2026.

TD Cowen Coverage Initiation

The Company is also pleased to announce that TD Cowen has initiated coverage on Cannara as of February 24, 2026. TD Cowen's research report on Cannara is available through their platform. Please note that any opinions or forecasts regarding the Company made by TD Cowen are theirs alone and neither represent the opinions or forecasts of Cannara or its management, nor imply that the Company endorses or approves such information, conclusions, or recommendations.

CONTACT

Nicholas?Sosiak, CPA, CA
Chief Financial Officer
nick@cannara.ca?
Zohar?Krivorot?
Founder & Chief Executive Officer 
zohar@cannara.ca?
 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

ABOUT CANNARA

Cannara Biotech Inc. (TSXV: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), is a vertically integrated producer of affordable premium-grade cannabis and cannabis-derivative products for the Canadian markets. Cannara owns two mega facilities based in Québec spanning over 1,600,000 sq. ft., providing the Company with 100,000 kg of potential annualized cultivation output. Leveraging Québec’s low electricity costs, Cannara’s facilities produce premium-grade cannabis products at an affordable price. For more information, please visit?cannara.ca.

CAUTIONARY STATEMENT REGARDING “FORWARD-LOOKING” INFORMATION

This news release may contain “forward-looking information” within the meaning of Canadian securities legislation (“forward-looking statements”). These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required under applicable securities legislation. Forward-looking statements relate to future events or future performance and reflect Company management’s expectations or beliefs regarding future events and include, but are not limited to, statements regarding the expected benefits of the Uplisting including enhanced visibility and liquidity for shareholders, and the Company’s ability to continue executing on its growth strategy.

In certain cases, forward-looking statements can be identified by the use of words such as “plans,” “expects” or “does not expect,” “is expected,” “budget,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur” or “be achieved” or the negative of these terms or comparable terminology. In this document, certain forward-looking statements are identified by words including “may,” “future,” “expected,” “intends” and “estimates.” By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those that are disclosed in, or implied by, such forward-looking information. These risks and uncertainties include, but are not limited to, the risk factors which are discussed in greater detail under “Risk Factors” in the Company’s AIF available on SEDAR+ at www.sedarplus.ca and under the “Investor Area” section of our website at https://www.cannara.ca/en/investor-area.

Other risks not presently known to the Company or that the Company believes are not significant could also cause actual results to differ materially from those expressed in its forward-looking statements. Although the forward-looking information contained herein is based upon what we believe are reasonable assumptions, readers are cautioned against placing undue reliance on this information since actual results may vary from the forward-looking information. Certain assumptions were made in preparing the forward-looking information concerning the availability of capital resources, business performance, market conditions, as well as customer demand. Consequently, all of the forward-looking information contained herein is qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments that we anticipate will be realized or, even if substantially realized, that they will have the expected consequences or effects on our business, financial condition or results of operation. Unless otherwise noted or the context otherwise indicates, the forward-looking information contained herein is provided as of the date hereof, and we do not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.


FAQ**

What strategic initiatives does Cannara Biotech Inc (LOVFF) plan to implement post-Uplisting to enhance its market visibility and attract institutional investors?

Cannara Biotech Inc plans to implement strategic initiatives post-Uplisting that include enhancing brand visibility through targeted marketing campaigns, expanding product offerings, strengthening partnerships, and improving investor relations to attract institutional investors.

How does Cannara Biotech Inc (LOVFF) plan to leverage its low electricity costs in Québec to maintain competitive pricing for its premium-grade cannabis products?

Cannara Biotech Inc. plans to leverage its low electricity costs in Québec by enhancing operational efficiency, reducing production expenses, and positioning its premium-grade cannabis products competitively in the market to attract cost-conscious consumers while ensuring quality.

In what ways does Cannara Biotech Inc (LOVFF) foresee the TSX Uplisting impacting its growth strategy and shareholder value over the next few years?

Cannara Biotech Inc (LOVFF) anticipates that the TSX uplisting will enhance its visibility, attract institutional investors, improve access to capital, and ultimately drive growth and shareholder value by increasing market liquidity and fostering strategic partnerships.

What are the key factors contributing to Cannara Biotech Inc (LOVFF)'s estimated annual cultivation output of 100,000 kg from its two mega facilities?

Key factors contributing to Cannara Biotech Inc (LOVFF)'s estimated annual cultivation output of 100,000 kg from its two mega facilities include state-of-the-art cultivation technology, optimal scale of operations, strategic location, and a focus on high-yield strains.

**MWN-AI FAQ is based on asking OpenAI questions about Cannara Biotech Inc (OTC: LOVFF).

Cannara Biotech Inc

NASDAQ: LOVFF

LOVFF Trading

0.22% G/L:

$1.343 Last:

500 Volume:

$1.343 Open:

mwn-alerts Ad 300

LOVFF Latest News

LOVFF Stock Data

$129,344,490
45,496,520
2.5%
3
N/A
Pharmaceuticals
Healthcare
CA
Vancouver

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App